Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients-A Multicenter Propensity Matched Analysis

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Gonçalves Pereira, João ^a,b   Oliveira, Bruno Serra ^c   Janeiro, Sérgio ^d   Estilita, Joana ^e   Monteiro, Catarina ^f   Salgueiro, Andrea ^f   Vieira, Alfredo ^g   Gouveia, Joao ^h   Paulino, Carolina ^a   Bento, Luis ^d   Póvoa, Pedro ^a,b  

^a HOSPITAL DE SÃO FRANCISCO XAVIER   (Portugal)

^b NOVA MEDICAL SCHOOL   (Portugal)

^c HOSPITAL DE SANTA MARIA   (Portugal)

^d HOSPITAL DE SÃO JOSÉ   (Portugal)

^e HOSPITAL DE FARO   (Portugal)

^f CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^g Unidade de Cuidados Intensivos   (Portugal)

^h HOSPITAL PULIDO VALENTE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; ETHNIC GROUP; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PORTUGUESE; PROPENSITY SCORE; RETROSPECTIVE STUDY; SEPSIS; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIA; CRITICAL ILLNESS; FEMALE; HUMANS; INFECTION; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PORTUGAL;

EID: 84869853144     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049845     Document Type: Article

References (37)

1. Drusano GL, (2004) Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2: 289-300.
2. Roberts J, Lipman J, Blot S, Rello J, (2008) Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care 14: 390.
3. Lipman J, Wallis SC, Rickard C, (1999) Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 43: 2559-2561.
4. De Jongh R, Hens R, Basma V, Mouton JW, Tulkens PM, et al. (2008) Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 61: 382-388.
5. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J, (2009) First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 35: 156-163.
6. Georges B, Conil JM, Seguin T, Dieye E, Cougot P, et al. (2008) Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables. Int J Clin Pharmacol Ther 46: 157-164.
7. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, et al. (2012) Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 16: R113.
8. Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, et al. (2007) Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 59: 285-291.
9. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J, (2009) A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 37: 2071-2078.
10. Tamma PD, Putcha N, Suh YD, Van Arendonk KJ, Rinke ML, (2011) Does prolonged beta-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infect Dis 11: 181.
11. Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37: 840-851; quiz 859.
12. Joffe MM, Rosenbaum PR, (1999) Invited commentary: propensity scores. Am J Epidemiol 150: 327-333.
13. Le GallJR, Lemeshow S, Saulnier F, (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270: 2957-2963.
14. Lodise TP Jr, Lomaestro B, Drusano GL, (2007) Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44: 357-363.
15. Nicolau DP, (2008) Pharmacodynamic optimization of beta-lactams in the patient care setting. Crit Care 12 (Suppl 4): S2.
16. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME, (2005) Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 5: 581-589.
17. Boselli E, Breilh D, Rimmele T, Guillaume C, Xuereb F, et al. (2008) Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med 36: 1500-1506.
18. Lorente L, Jimenez A, Martin MM, Iribarren JL, Jimenez JJ, et al. (2009) Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 33: 464-468.
19. Knaus WA, Draper EA, Wagner DP, Zimmerman JE, (1985) APACHE II: a severity of disease classification system. Crit Care Med 13: 818-829.
20. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, et al. (2006) Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 28: 122-127.
21. Lipman J, Wallis SC, Rickard CM, Fraenkel D, (2001) Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 27: 363-370.
22. Bodey GP, Ketchel SJ, Rodriguez V, (1979) A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 67: 608-616.
23. Lipman J, Wallis SC, Boots RJ, (2003) Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 97: 1149-1154.
24. Shikuma LR, Ackerman BH, Weaver RH, Solem LD, Strate RG, et al. (1990) Effects of treatment and the metabolic response to injury on drug clearance: a prospective study with piperacillin. Crit Care Med 18: 37-41.
25. Conil JM, Georges B, Mimoz O, Dieye E, Ruiz S, et al. (2006) Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Intensive Care Med 32: 2063-2066.
26. Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R, Lizan-Garcia M, (2008) Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 36: 674-680.
27. Baptista JP, Udy AA, Sousa E, Pimentel J, Wang L, et al. (2011) A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 15: R139.
28. Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CM, et al. (2011) Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol 11: 3.
29. Roberts JA, De Waele JJ, Dimopoulos G, Koulenti D, Martin C, et al. (2012) DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect Dis 12: 152.
30. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, et al. (2010) Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14: R126.
31. Bourget P, Lesne-Hulin A, Le Reveille R, Le Bever H, Carsin H, (1996) Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 40: 139-145.
32. Ulldemolins M, Roberts JA, Lipman J, Rello J, (2011) Antibiotic dosing in multiple organ dysfunction syndrome. Chest 139: 1210-1220.
33. Chapuis TM, Giannoni E, Majcherczyk PA, Chiolero R, Schaller MD, et al. (2010) Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 14: R51.
34. Singer M, Glynne P, (2005) Treating critical illness: the importance of first doing no harm. PLoS Med 2: e167.
35. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, et al. (2010) Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36: 332-339.
36. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA, (2012) Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Annals of Intensive Care 2: 35.
37. Goncalves-Pereira J, Povoa P, (2011) Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 15: R206.